ACADIA Pharmaceuticals Raises FY2026 Sales Guidance from $1.220B-$1.280B to $1.240B-$1.300B vs $1.242B Est

Benzinga Newsdesk www.benzinga.com Positive 94.1%

Neg 0% Neu 0% Pos 94.1%

ACADIA Pharmaceuticals (NASDAQ:ACAD) raises FY2026 sales outlook from $1.220 billion-$1.280 billion to $1.240 billion-$1.300 billion vs $1.242 billion estimate.